Vaxcyte
PCVX
187 hedge funds and large institutions have $3.15B invested in Vaxcyte in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 70 increasing their positions, 63 reducing their positions, and 31 closing their positions.
99% more call options, than puts
Call options by funds: $6.92M | Put options by funds: $3.47M
11% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 63
1.8% more ownership
Funds ownership: 103.28% → 105.08% (+1.8%)
6% less funds holding
Funds holding: 198 → 187 (-11)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
19% less capital invested
Capital invested by funds: $3.9B → $3.15B (-$745M)
29% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$81.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$69.5M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$60.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$48.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$30.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$46.9M |
| 2 |
O
OrbiMed
New York
|
-$23.5M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$23.3M |
| 4 |
DM
Deerfield Management
New York
|
-$17.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.3M |
PCVX Hedge Fund Activity: Q1 2023 in Review
187 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2023, worth a combined $3.15B — down 19% from $3.9B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of PCVX and 22 opened new positions — a net loss of 9 holders — while 63 trimmed existing stakes and 70 added.
The largest buyer was Carlyle Group, opening a new position worth an estimated $81.6M. The largest seller was Avidity Partners Management, cutting an estimated $46.9M.
- 187 institutional investors held Vaxcyte (PCVX) as of Q1 2023, down from 198 in Q4 2022.
- Funds reported $3.15B of Vaxcyte stock for Q1 2023, down 19% quarter-over-quarter.
- 22 funds opened new Vaxcyte positions in Q1 2023 and 31 closed out, a net change of -9 holders.
- The largest Vaxcyte buyer in Q1 2023 was Carlyle Group, an estimated $81.6M added.
- The largest Vaxcyte seller in Q1 2023 was Avidity Partners Management, an estimated $46.9M sold.
Based on aggregated 13F filings for Q1 2023.